ライフサイエンスコーパス: plaque-forming

1 alpha-P and BACE1 are elevated in aggressive plaque-forming 5XFAD transgenic mice, and BACE1, eIF2alp

2 The use of a small plaque-forming A36R gene deletion mutant to select spont

3 ut they were robust in viral replication and plaque forming ability.

4 transdominant or potentiating effect on the plaque-forming ability of infectious DNA from wild-type

5 fold lower titers) in nondividing cells, and plaque-forming ability was severely compromised.

6 ss-links resulted in very severely decreased plaque-forming ability, along with an increased mutageni

7 showed greatly reduced (around 100,000-fold) plaque-forming ability.

8 in hydrolase (gp61) that is essential for N4 plaque-forming ability.

9 ssay of full-length transcripts to determine plaque-forming ability; and (iv) analysis of proteins ex

10 Rs of the APP superfamily, including amyloid plaque-forming and non-amyloid plaque-forming species, a

11 tly increased microglial density and size in plaque-forming areas of hippocampus and frontal, entorhi

12 re evaluated by using real-time PCR, a viral plaque-forming assay, and immunofluorescence staining.

13 V-1 inactivation was measured in a sensitive plaque-forming assay, and the corresponding level of CD4

14 Viral plaque forming assays evaluated G207 replication.

15 Using the iLLO strain in plaque-forming assays, we demonstrated an additional req

16 Unlike CJ83193, which exhibits limited plaque-forming capability in Vero cells and expresses li

17 their capacity to mount an in vitro antibody plaque-forming cell (PFC) response to sheep erythrocytes

18 sed in their ability to generate an in vitro plaque-forming cell (PFC) response to sheep erythrocytes

19 acity of splenocytes to generate an in vitro plaque-forming cell (PFC) response to sheep erythrocytes

20 of spleen cells to mount a primary, in vitro plaque-forming-cell (PFC) response to sheep erythrocytes

21 Plaque-forming characteristics and RFLP analyses of phag

22 with UBE2D1 fail not only to complement the plaque-forming defect of an ICP0-null mutant virus but a

23 ICP0-null mutant HSV-1 exhibits a plaque-forming defect of up to 3 orders of magnitude in

24 prototype of a family of large, icosahedral, plaque-forming, double-stranded-DNA-containing viruses t

25 prototype of a family of large, icosahedral, plaque-forming, dsDNA viruses that replicate in certain

26 lular replication measured by a reduction in plaque-forming efficiency and plaque size.

27 that depletion of CoREST should improve the plaque-forming efficiency and replication of ICP0 null m

28 man cytomegalovirus (HCMV) infection, as its plaque-forming efficiency increased in MORC3-depleted ce

29 Plaque-forming efficiency was enhanced at least 50-fold

30 effect only in human cell lines, with large plaques forming in HeLa cells, with minimal cell associa

31 Tg2576 beta-amyloid-plaque-forming mice should be a useful system for assess

32 of this unique FKBP-dependence, spontaneous plaque-forming mutants of phi X174 were isolated on a sl

33 ed in large numbers (>5 x 10(8)/ml), and the plaque-forming particle (PFP) titer dropped approximatel

34 he ratios of cell-killing particles (CKP) to plaque-forming particles (PFP) were 1:1 and 7:1 in popul

35 ically active particles of infectious virus (plaque-forming particles [PFPs]) and different classes o

36 ne with active alleles of Bax/Bak results in plaque-forming phages.

37 The growth of the ICP10DeltaPK virus and its plaque-forming potential were restored to wild-type leve

38 tein, and the virus had wild-type growth and plaque-forming properties.

39 Furthermore, two naturally occurring plaque-forming revertants were analyzed and shown to hav

40 in a location unique to APP genes of amyloid plaque-forming species and absent in all other genes sur

41 6) present only in the APP gene from amyloid plaque-forming species, absent in all APP-like-proteins'

42 uding amyloid plaque-forming and non-amyloid plaque-forming species, and of prions (27 different DNA

43 es that often equal and sometimes exceed the plaque-forming titer of the inducing phage.

44 tion of the dengue 2 and dengue 3 viruses in plaque forming unit (PFU mL(-)(1)), giving detection lim

45 ectrodes enable the detection of less than 1 plaque forming unit (pfu)/mL in a direct EIS assay.

46 arget FAdVs and the electric signal up to 10 Plaque forming unit (PFU)/mL with a limit of detection (

47 Human cytomegalovirus (5 x 10(3) plaque forming unit in 0.1 ml Hank's balanced salt solut

48 acyclovir-resistant strain) was measured by plaque-forming unit (PFU) inhibition.

49 5% chlorine was sufficient to ensure <8 Phi6 plaque-forming unit (PFU)/cm(2) in all tests.

50 tion values, we injected intradermally 10(9) plaque-forming unit adenovirus with the following transg

51 I.v. injections of GLV-1h68 (1x10(7) plaque-forming unit per mouse) into nude mice with estab

52 gle intratumoral administration of 2 x 10(9) plaque-forming unit(s) of Ad-OC-E1a.

53 l-channel PSPWB for S-OIV is 30 PFU/mL (PFU, plaque-forming unit), which was calculated from the fitt

54 requencies ranging from 10(-5) to 10(-9) per plaque-forming unit.

55 oratory RUB strains and as low a dose as one plaque-forming unit.

56 (HCMV) at a multiplicity of infection of 0.1 plaque-forming unit/cell and remained > 95% viable even

57 l load (adjusted mean, 250.7 vs. 757.7 log10 plaque-forming-unit equivalents [PFUe] x hours per milli

58 roup were 59.9, 73.7, 133.4, and 500.9 log10 plaque-forming-unit equivalents x hours per milliliter,

59 es the viral titers remain high (10(5)-10(8) plaque forming units (pfu) per gram of tissue) for the l

60 ure injections of > 20 nanoliters of a 10(8) plaque forming units (pfu) per ml solution of virus were

61 Ad5CMVcatalase, with up to 10 plaque forming units (pfu) per neuron, did not affect ce

62 1 through 5 in four dose cohorts: 1 x 10(9) plaque forming units (pfu), 1 x 10(10) pfu, 3 x 10(10) p

63 st generation assay is 10(2) and 10(2)-10(8) plaque forming units (pfu), respectively.

64 at a multiplicity of infection (MOI) of 10.0 plaque forming units (pfu)/cell at 48 hours.

65 infect SK-ChA-1 and HeLa cells at 10 and 100 plaque forming units (pfu)/cell, followed by FACS analys

66 re inoculated intramuscularly with 6 x 10(3) plaque forming units (PFUs) of MP-12 vaccine.

67 xpressing Cre recombinase (Ad-Cre; 2 x 10(7) plaque forming units [PFU]) and adeno-associated viral v

68 Murine cytomegalovirus (9 x 10(2) plaque forming units [pfu]) was injected into the suprac

69 Each mouse received 1 x 10(9) plaque forming units administered i.v. 48 hr before the

70 ion of MV-CEA at a total dose of 1.8 x 10(6) plaque forming units as assessed by magnetic resonance i

71 were treated with a total dose of 8 x 10(7) plaque forming units of MV-CEA, administered i.v.

72 4 followed by intramuscular injection of 108 plaque forming units of MVA-CMDR at weeks 12 and 24.

73 sed by the reduction in viral genomes and/or plaque forming units on treatment.

74 pounds exhibiting clinically relevant (10(1) plaque forming units) limit of detection.

75 ins of HSV-1-sensitive A/J mice at 2 x 10(6) plaque forming units, G47Delta was as safe as G207.

76 of an adenoviral construct (10 muL; 8x10(9) plaque forming units/mL) encoding green fluorescent prot

77 Plaque-forming units (106 or 108) of an adenovirus conta

78 rs, one eye was injected once with 8 X 10(8) plaque-forming units (20 microl) of the viral vector, wh

79 laque-forming units (low dose) and 4 x 10(8) plaque-forming units (high dose) of rPLTP.AdV into mice,

80 After intravenous infusion of 4 x 10(7) plaque-forming units (low dose) and 4 x 10(8) plaque-for

81 lthy adults were inoculated with 5.0 log(10) plaque-forming units (PFU) (n = 30) or 3.0 log10 PFU (n

82 ine at 3 million, 20 million and 100 million plaque-forming units (PFU) and homologous VSV-Ebola vacc

83 t time points after inoculation of 2 x 10(4) plaque-forming units (PFU) HSV-1 (KOS strain) or an equi

84 roduces 45% survivors at a dose of 3 x 10(4) plaque-forming units (pfu) in a 9-day-old mouse model of

85 ted Ebola virus disease when used at 2 x 107 plaque-forming units (PFU) in a trial in Guinea.

86 ived 1 subcutaneous dose of 10, 100, or 1000 plaque-forming units (PFU) in cohorts of 3.

87 g ZIKV in oral samples with sensitivity of 5 plaque-forming units (PFU) in less than 40 min.

88 IL-17 cDNA targeted to the liver (5 x 10(9) plaque-forming units (PFU) intravenous) resulted in a tr

89 human bilirubin-UGT1 (Ad-hBUGT1) (3 x 10(9) plaque-forming units (pfu) intravenously) in adult bilir

90 3) were injected with 1 x 10(6) to 5 x 10(8) plaque-forming units (pfu) of Ad-hSSTr2-TK.

91 by subcutaneous inoculation of either 10(3) plaque-forming units (PFU) of DENV-1 or 10(5) PFU of DEN

92 9 days after intranasal infection with 10(5) plaque-forming units (pfu) of Influenza A strain WSN/33.

93 Rhesus macaques given 5 x 10(4) or 1 x 10(5) plaque-forming units (pfu) of Rift Valley fever (RVF) MP

94 infected with 10(4), 10(5), 10(6), or 10(7) plaque-forming units (pfu) of the Dryvax strain of the v

95 l BALB/c mice were inoculated with 4 X 10(4) plaque-forming units (PFU) of the KOS strain of HSV-1 us

96 t doses (3 x 10(8), 1 x 10(8), and 3 x 10(7) plaque-forming units (pfu) of the recombinant adenoviral

97 ty results in volunteers receiving 3 x 10(5) plaque-forming units (pfu) of the recombinant vesicular

98 ccination with 10(8.1), 10(7.2), and 10(7.0) plaque-forming units (pfu) of vaccinia virus per millili

99 This strategy yielded >1 x 10(3) plaque-forming units (pfu) of virus per ml of supernatan

100 fter nude mice were injected i.p. with 10(7) plaque-forming units (pfu) of WT, TK-, VGF-, or vvDD-GFP

101 f vaccine ranging from 300,000 to 50 million plaque-forming units (PFU) or placebo.

102 3 strain Dearing (T3D) at 0, 0.1, 1, and 10 plaque-forming units (PFU) per cell for 48 h.

103 OOP where CBA/J mice infected with 1 x 10(6) plaque-forming units (PFU) reovirus 1/L develop follicul

104 ymic BALB/c mice was injected with 1 x 10(4) plaque-forming units (PFU) to 2 x 10(4) PFU of herpes si

105 eived ONYX-015 at a daily dose of 1 x 10(10) plaque-forming units (pfu) via intratumoral injection fo

106 atment groups: ChimeriVax-WN02 3.7- x -10(5) plaque-forming units (PFU), 3.7 x 10(4) PFU, 3.7 x 10(3)

107 ore permissive SCID mice with 10(5) or 10(7) plaque-forming units (PFU), respectively.

108 were injected with doses of up to 1 x 10(11) plaque-forming units (pfu).

109 o be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu).

110 ngeal virus titers peaked at 10(5.0)-10(6.0) plaque-forming units (pfu)/g of tissue from days 2 throu

111 A first-dose MTD of 12 x 10(9) plaque-forming units (PFU)/m(2) was established for outp

112 mits of detection for EBOV and SUDV were 465 plaque-forming units (PFU)/mL (1010 copies/mL) and 324 P

113 eceiving infectious titers of > or = 4X10(9) plaque-forming units (pfu)/mL showed endothelial activat

114 ection of this RT-LAMP assay was 2.8 x 10(2) plaque-forming units (PFU)/test and 1 x 10(3) PFU/test w

115 in 96-well plates was approximately 2 x 106 plaque-forming units (pfu)/well.

116 s, as revealed by their LD50 values: PR8, 32 plaque-forming units (PFU); HA(Min), 1.7 x 10(3) PFU; NA

117 d hospitalized patients (log(10) 3.7 +/- 1.7 plaque-forming units (PFUs)/mL vs 2.4 +/- 1.1 PFUs/mL, P

118 various vector doses [1 x 10(6) to 2 x 10(9) plaque-forming units (PFUs)] prior to imaging.

119 tion (one 0.5 mL dose containing 2.5 x 10(4) plaque-forming units [PFU] of TDV-1; 6.3 x 10(3) PFU of

120 After ocular challenge with 2 x 10(5) plaque-forming units [pfu] per eye of HSV-1 strain McKra

121 needle with undiluted vaccine (dose, 10(7.8) plaque-forming units [pfu] per milliliter), a 1:10 dilut

122 n of HSV-1 strain McKrae (25 microL of 10(5) plaque-forming units [PFU]) in the scarified rabbit corn

123 Administration of a high dose (4 x 10(9) plaque-forming units [pfu]) of Av1ALAPH81 to mice result

124 ose levels of Adp53 (1 x 10(6) to 1 x 10(11) plaque-forming units [PFU]).

125 in these models at low doses of EBOV (</=100 plaque-forming units [PFU]).

126 e doses of the rVSV-ZEBOV vaccine (3 million plaque-forming units [PFU], 20 million PFU, or 100 milli

127 1 of 3 lots of rVSVDeltaG- ZEBOV-GP (2 x 107 plaque-forming units [pfu], n = 797; combined-lots group

128 inally in adult pigmented rabbits (5 x 10(4) plaque-forming units [pfu]/eye).

129 ildren (mean peak titer, 10(4.3) vs. 10(2.5) plaque-forming units [pfu]/mL), indicating that the 1030

130 le intramuscular dose of rVSV-ZEBOV (2x10(7) plaque-forming units administered in the deltoid muscle)

131 , gene transfer was performed with 1 x 10(9) plaque-forming units by intravenous tail injection, 48 h

132 knockout (ko) mice were infected with 10(5) plaque-forming units CVB3.

133 An HBRV dose of > or =8 x 10(6) plaque-forming units has demonstrated 68.8%-76.6% effica

134 + mice and was associated with increased RSV plaque-forming units in lung homogenates.

135 48/404 vaccine was infectious at 104 and 105 plaque-forming units in RSV-naive children and was broad

136 In vivo, Ad-hACE2-eGFP infection (2x10(6) plaque-forming units intracerebroventricularly) produced

137 Mice were then given 10(9) plaque-forming units of a control vector (Ad.LacZ) or Ad

138 A single i.v. administration of 2 x 10(9) plaque-forming units of Ad-hOC-E1 inhibited the growth o

139 Using 1x10(9) plaque-forming units of Ad-LacZ (multiplicity of infecti

140 Intralesional injection of 5 x 10(8) plaque-forming units of AdCIFN-beta (but not AdLacZ) era

141 a single intravenous injection of 3 x 10(9) plaque-forming units of AdmVLDLR.

142 tu with saline alone (control), or 9 x 10(9) plaque-forming units of AdV-FasL.

143 First, 1.0 x 10(9) plaque-forming units of AdvBcl-2 in phosphate-buffered s

144 delay in healing, with vehicle, 106, or 108 plaque-forming units of an adenovirus containing the pla

145 Ischemic excisional wounds treated with 108 plaque-forming units of an adenovirus containing the pla

146 mean +/- SD, p < 0.05) when treated with 106 plaque-forming units of an adenovirus containing the pla

147 ean +/- SD, p < 0.001) when treated with 108 plaque-forming units of an adenovirus containing the pla

148 nstillation of either 1 x 10(9) or 4 x 10(9) plaque-forming units of an adenovirus that expresses an

149 A dose of 2 x 10(9) plaque-forming units of apoE4-expressing adenovirus redu

150 HepG2 cells were infected with 2 x 10(5) plaque-forming units of AvRB15 for 5, 10, 15, and 24 h.

151 bjects were inoculated intranasally with 100 plaque-forming units of coxsackievirus A21.

152 ) were infected intraperitoneally with 10(6) plaque-forming units of CVB3.

153 surfactant-based system to deliver 4 x 10(9) plaque-forming units of E1a-/E3- recombinant adenovirus

154 45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compare

155 Dams were challenged with 1 x 10(4) plaque-forming units of GPCMV in the third trimester.

156 ere intracamerally infected with 2.5 x 10(4) plaque-forming units of infectious HSV-1.

157 fter supraciliary injection with 9.0 x 10(2) plaque-forming units of MCMV, 7 of 10 NK-depleted mice d

158 amide, were infected subretinally with 5x102 plaque-forming units of MCMV.

159 DBA/1 LacJ mice were administered 3 x 10(8) plaque-forming units of mIL-12 i.p. in a nonreplicating

160 ow-femtomole range, as estimated by titering plaque-forming units of MS2.

161 (1:1) to receive a single dose of 2 x 10(8) plaque-forming units of MVA-BN-Filo or saline placebo.

162 after intradermal vaccination with 5 x 10(7) plaque-forming units of MVA85A.

163 ) scid mice, which received 0.5 or 5 x 10(6) plaque-forming units of R4009, either were coinoculated

164 Patients with mCRPC received 2x10(8) plaque-forming units of recombinant vaccinia PSA-Tricom

165 ults were inoculated intranasally with 10(6) plaque-forming units of rHMPV-SHs.

166 BALB/c mice were infected with 10(7) plaque-forming units of RSV, in the presence or absence

167 provider to subcutaneous injections of 10(8) plaque-forming units of TG4010 or placebo from the begin

168 Rabbit eyes were infected with 10(5) plaque-forming units of the Dryvax strain of vaccinia vi

169 ere inoculated subcutaneously with 3.0 log10 plaque-forming units of the Guanarito virus prototype st

170 rsity of Wisconsin solution containing 10(9) plaque-forming units of the recombinant adenovirus.

171 ulation of CMV ocular infection, 9.0 x 10(2) plaque-forming units of the Smith strain of murine CMV (

172 her 2.5 x 10(5), 2.5 x 10(6), or 2.5 x 10(7) plaque-forming units of vaccine.

173 All mice vaccinated with 1 x 10(7) plaque-forming units of wild-type E7-vaccinia showed pro

174 enged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV.

175 V)CFTR.10 at doses of 3 x 10(6) to 2 x 10(9) plaque-forming units over 9 months by endobronchial spra

176 ion with RAd35 beta-Gal at 30, 100, and 1000 plaque-forming units per cell (pfu/cell), expression of

177 SERCA virus titers >5 to 6 plaque-forming units per cell produced overcrowding of A

178 At higher input multiplicities (10 plaque-forming units per cell), ADsubUL82 grew nearly as

179 ricted at low input multiplicities (0.01-0.1 plaque-forming units per cell), producing a yield that i

180 At mois > 3 plaque-forming units per cell, virus replication and pro

181 CA virus titer were maintained within 1 to 4 plaque-forming units per cell.

182 tectable by flow cytometry at an MOI of > 30 plaque-forming units per cell.

183 omegalovirus promoter at approximately 10(8) plaque-forming units per cornea for 48 hours.

184 after corneal scarification with 1.5 x 10(6) plaque-forming units per eye with one of the following r

185 e treated with CMX001 had titers 3-5 log(10) plaque-forming units per gram of tissue lower than sampl

186 ee animals received 1 x 10(10) to 1 x 10(11) plaque-forming units per kilogram by intravenous injecti

187 target, at low concentration values of 3-45 plaque-forming units per milliliter (pfu mL(-1)) with de

188 toilets at an initial concentration of 10(7) plaque-forming units per milliliter (PFU mL(-1)), were n

189 ney cells and achieved levels of 10(6)-10(7) plaque-forming units per ml of cell supernatant 6 days a

190 dicated by: high titres of MARV (10(3)-10(5) plaque-forming units per mL); development of leucocytosi

191 Rats transduced with 1x10(9) plaque-forming units show decremental cardiac luciferase

192 hosphamide-suppressed animals, the ratios of plaque-forming units to LD50 decreased by at least four

193 nfection, but it did not alter the ratios of plaque-forming units to LD50 or affect the HSV-induced i

194 s evidenced by decreased viral titers (10(5) plaque-forming units to undetectable), and restoration o

195 1) (P<0.05 for 1x10(9), 1x10(8), and 1x10(7) plaque-forming units versus control adenovirus-expressin

196 say, 50 microm BIP caused a 50% reduction in plaque-forming units with either virus.

197 es of either CCSV or test vaccine (2.5x10(5) plaque-forming units) by 15 puncture scarification in do

198 injection of recombinant adenoviruses (10(9) plaque-forming units) encoding the ligand-binding ectodo

199 The effect of rat CMV (RCMV) (5x105 plaque-forming units) on TVS (neointimal index, NI) and

200 enous (IV) injection of GLV-1h153 (1 x 10(7) plaque-forming units) or phosphate buffered saline was t

201 given two doses of 89-12 (containing 1x10(5) plaque-forming units) or placebo, and 213 were followed

202 a single injection of AdRSVpHyde (5 x 10(9) plaque-forming units) reduced DU145 tumors in nude mice

203 njection of tumors with Ad.mIL-12 (1 x 10(9) plaque-forming units) results in a complete tumor regres

204 ro with adenovirus murine FVIII (3.3 x 10(5) plaque-forming units) was 87%.

205 lication-incompetent adenovirus (0-2 x 10(9) plaque-forming units) with the E1 region deleted (n = 8)

206 In rats dosed with this agent (2.2 x 10(9) plaque-forming units), the time course of expression was

207 ) were injected with AdSDF-1alpha (5 x 10(8) plaque-forming units), there was an accumulation of dend

208 ty when inoculated i.v. in high doses (10(9) plaque-forming units).

209 fection with the unadapted virus (ID(50) = 5 plaque-forming units).

210 The labeled phage (10(9) plaque-forming units, 1-3.7 MBq) was administered either

211 ation with rVSV-ZEBOV (one dose of 2 x 10(7) plaque-forming units, administered intramuscularly in th

212 ice were infected with adenovirus (3 x 10(9) plaque-forming units, intravenously) containing either C

213 1, with subsequent monthly boosts of 1x10(9) plaque-forming units, starting on day 15.

214 in cell cultures ranged from 10(1) to 10(3) plaque-forming units/0.5 mL of a 10% stool suspension.

215 i.v. administration of CG8840 (3.33 x 10(9) plaque-forming units/animal on day 1) and docetaxel (20

216 of 100% at a multiplicity of infection of 25 plaque-forming units/cell and persistence of foreign gen

217 ion of breast cancer cells with AdWTp53 (100 plaque-forming units/cell) resulted in 100% loss of the

218 ts received 3 oral doses of vaccine (4 x 105 plaque-forming units/dose) or placebo at ages approximat

219 AT(-)) (low phenotypic reactivator) at 10(4) plaque-forming units/eye.

220 AT(-)) (low phenotypic reactivator) at 10(4) plaque-forming units/eye.

221 Neurotoxicity studies, as defined by plaque-forming units/LD(50), performed in HSV-1-sensitiv

222 ng units/mL; after 3 weeks, </= 4 mL x 10(8) plaque-forming units/mL every 2 weeks).

223 ere labeled by directly injecting 8 x 10(10) plaque-forming units/ml of adenoviral GFP in 20-100 micr

224 administered intratumorally in week 1 (10(6) plaque-forming units/mL), then in week 4 and every 2 wee

225 l vector used at identical titer (1 x 10(10) plaque-forming units/ml).

226 n week 4 and every 2 weeks thereafter (10(8) plaque-forming units/mL).

227 MV-ERV grew to 10(6) plaque-forming units/mL, slightly lower than the parenta

228 egan in week 1 (first dose, </= 4 mL x 10(6) plaque-forming units/mL; after 3 weeks, </= 4 mL x 10(8)

229 ns of Ad-FHIT, at a total dose of 3 x 10(10) plaque-forming units/tumor for H1299 tumors and 4 x 10(1

230 eas were inoculated bilaterally with 2x10(6) plaque-forming-units (PFU) of adenovirus type 5 (Ad5) af

231 5804Han89 (CDV(5804)), the small- and large-plaque-forming variants of the CDV vaccine strain Onders

232 odnaviridae, is a large double-stranded DNA, plaque-forming virus that infects the unicellular green

233 n yet completely eliminated the formation of plaque-forming virus.

234 e of a family of large, double-stranded DNA, plaque-forming viruses that infect certain eukaryotic ch

235 hloroviruses are large, double-stranded-DNA, plaque-forming viruses that infect certain eukaryotic ch